Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants

International Journal of Pharmaceutics

Volumn 398, Issue 1-2, 2010, Pages 123-129

  Wei, Gang ^a   Jin, Liang ^a   Xu, Lingjie ^a   Liu, Yu ^a   Lu, Weiyue ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Biodegradable implants; Flow cytometry; Immunity; Release; Thymopentin (TP5)

Indexed keywords

POLYGLACTIN; POLYLACTIDE; THYMOPENTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABLE IMPLANT; CD4 CD8 RATIO; CELLULAR IMMUNITY; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; FLOW CYTOMETRY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SURVIVAL RATE;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; LACTIC ACID; MALE; POLYESTERS; POLYGLYCOLIC ACID; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TECHNOLOGY, PHARMACEUTICAL; THYMOPENTIN;

EID: 77956228132     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.036     Document Type: Article

References (25)

1. Afeltra A., Galeazzi M., Basso P., Pietrucci A., De Pita O., Ferri G.M., Porzio F., Bonomo L. Immune imbalance in the synovial fluid of rheumatoid arthritis patients: effects of intra-articular injection of thymopentin. J. Biol. Regul. Homeostatic Agents 1991, 5:71-75.
2. Ali S.A.M., Doherty P.J., Williams D.F. Molecular biointeractions of biomedical polymers with extracellular exudate and inflammatory cells and their effects on the biocompatibility, in vivo. Biomaterials 1994, 15:779-785.
3. Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLGA microsphere. Adv. Drug Del. Rev. 1997, 28:5-24.
4. Audhya T.K., Goldstein G. Thymopentin: stability considerations and potency by various routes of administration. Surv. Immunol. Res. 1985, 4(Suppl. 1):17-23.
5. Bleich J., Müller B.W. Production of drug loaded microparticles by the use of supercritical gases with the aerosol solvent extraction system (ASES) process. J. Microencapsul. 1996, 13:131-139.
6. Conti B., Panico M., Ventura C.A., Giunchedi P., Puglisi G. Thymopentin loaded microsphere preparation by w/o/w emulsion technique: in vitro/ex vivo evaluation. J. Microencapsul. 1997, 14:303-310.
7. Eperon S., Bossy-Nobs L., Petropoulos I.K., Gurny R., Guex-Crosier Y. A biodegradable drug delivery system for the treatment of postoperative inflammation. Int. J. Pharm. 2008, 352:240-247.
8. Friedmann N. Thymopentin: safety overview. Surv. Immunol. Res. 1985, 4(Suppl. 1):139-148.
9. Gao J., Ding X., Chu C., Lu L., Zhang Y., Chen Y., Fan W., Li G., Gao S. Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats. Eur. J. Pharm. Sci. 2009, 36:572-579.
10. Goldstein G., Audhya T.K. Thymopoietin to thymopentin: experimental studies. Surv. Immunol. Res. 1985, 4(Suppl. 1):1-10.
11. Goldstein G., Scheid M.P., Boyse E.A., Schlesinger D.H., Van Wauwe J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 1979, 204:1309-1310.
12. Gonser S., Weber E., Folkers G. Peptides and polypeptides as modulators of the immune response: thymopentin-an example with unknown mode of action. Pharm. Acta Helv. 1999, 73:265-273.
13. He W., Jiang X., Zhang Z.R. Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin. J. Pharm. Sci. 2008, 97:2250-2259.
14. Islam D., Lindberg A.A., Christens B. Peripheral blood cell preparation influences the level of expression of leukocyte cell surface markers as assessed with quantitative multicolor flow cytometry. Cytometry 1995, 22:128-134.
15. Jahno V.D., Ribeiro G.B., dos Santos L.A., Ligabue R., Einloft S., Ferreira M.R., Bombonato-Prado K.F. Chemical synthesis and in vitro biocompatibility tests of poly (l-lactic acid). J. Biomed. Mater. Res. A 2007, 83:209-215.
16. Janeway C.A. The T cell receptor as a multicomponent signaling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu. Rev. Immunol. 1992, 10:645-674.
17. Menei P., Daniel V., Montero-Menei C., Brouillard M., Pouplard-Barthelaix A., Benoit J.P. Biodegradation and brain tissue reaction to poly(d,l-lactide-co-glycolide) microspheres. Biomaterials 1993, 14:470-478.
18. Negrín C.M., Delgado A., Llabrés M., Évora C. Methadone implants for methadone maintenance treatment. In vitro and in vivo animal studies. J. Control. Release 2004, 95:413-421.
19. Ramchandani M., Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J. Control. Release 1998, 54:167-175.
20. Singh V.K., Biswas S., Mathur K.B., Haq W., Garg S.K., Agarwal S.S. Thymopentin and splenopentin as immunomodulators. Current status. Immunol. Res. 1998, 17:345-368.
21. Tracy M.A., Ward K.L., Firouzabadian L. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999, 11:1057-1062.
22. Veys E.M., Hermanns P., Goldstein G., Kung P., Schindler J., Van Wauwe J. Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents. Int. J. Immunopharmacol. 1981, 3:313-319.
23. Wang L., Zhang Y., Tang X. Characterization of a new inhalable thymopentin formulation. Int. J. Pharm. 2009, 375:1-7.
24. Yin Y., Chen D., Qiao M., Lu Z., Hu H. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J. Control. Release 2006, 116:337-345.
25. Zhou T., Lewis H., Foster R.E., Schwendeman S.P. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release 1998, 55:281-295.